$12.52
-0.08[-0.63%]
At close: Apr 23
$12.52
0[0.00%]
After Hours: 4:00PM EDT
Pliant Therapeutics
(NASDAQ:PLRX)Pliant Therapeutics Stock (NASDAQ:PLRX), Analyst Ratings, Price Targets, Predictions
Pliant Therapeutics Inc has a consensus price target of $45.38, established from looking at the 55 latest analyst ratings. The last 3 analyst ratings were released from Needham, Needham, and RBC Capital on April 10, 2024, March 12, 2024, and March 5, 2024. With an average price target of $43.33 between Needham, Needham, and RBC Capital, there's an implied 246.11% upside for Pliant Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
RBC Capital
HC Wainwright & Co.
Cantor Fitzgerald
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Pliant Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 203.51% | Needham | Joseph Stringer | → $38 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 203.51% | Needham | Joseph Stringer | → $38 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 331.31% | RBC Capital | Brian Abrahams | $50 → $54 | Maintains | Outperform | Get Alert |
| 02/28/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 283.39% | HC Wainwright & Co. | Ed Arce | → $48 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 299.36% | RBC Capital | Brian Abrahams | $53 → $50 | Maintains | Outperform | Get Alert |
| 02/28/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 203.51% | Needham | Joseph Stringer | → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/05/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 203.51% | Needham | Joseph Stringer | $45 → $38 | Maintains | Buy | Get Alert |
| 02/05/2024 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 283.39% | HC Wainwright & Co. | Ed Arce | $52 → $48 | Maintains | Buy | Get Alert |
| 11/10/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 323.32% | RBC Capital | Brian Abrahams | $54 → $53 | Maintains | Outperform | Get Alert |
| 10/04/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 259.42% | Needham | Joseph Stringer | → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 315.34% | HC Wainwright & Co. | Ed Arce | $50 → $52 | Maintains | Buy | Get Alert |
| 09/27/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 259.42% | Needham | Joseph Stringer | → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 259.42% | Needham | Joseph Stringer | → $45 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 299.36% | HC Wainwright & Co. | Ed Arce | → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 403.19% | Cantor Fitzgerald | Pete Stavropoulos | → $63 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 283.39% | JP Morgan | Eric Joseph | $47 → $48 | Maintains | Overweight | Get Alert |
| 08/10/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 315.34% | Oppenheimer | Jeff Jones | $51 → $52 | Maintains | Outperform | Get Alert |
| 08/10/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 331.31% | RBC Capital | Brian Abrahams | $57 → $54 | Maintains | Outperform | Get Alert |
| 08/10/2023 | PLRX | Buy Now | Pliant Therapeutics | $12.52 | 299.36% | HC Wainwright & Co. | Ed Arce | → $50 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Pliant Therapeutics (PLRX)?
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by Needham on April 10, 2024. The analyst firm set a price target for $38.00 expecting PLRX to rise to within 12 months (a possible 203.51% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pliant Therapeutics (PLRX)?
The latest analyst rating for Pliant Therapeutics (NASDAQ: PLRX) was provided by Needham, and Pliant Therapeutics reiterated their buy rating.
When was the last upgrade for Pliant Therapeutics (PLRX)?
There is no last upgrade for Pliant Therapeutics.
When was the last downgrade for Pliant Therapeutics (PLRX)?
There is no last downgrade for Pliant Therapeutics.
When is the next analyst rating going to be posted or updated for Pliant Therapeutics (PLRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pliant Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pliant Therapeutics was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Pliant Therapeutics (PLRX) correct?
While ratings are subjective and will change, the latest Pliant Therapeutics (PLRX) rating was a reiterated with a price target of $0.00 to $38.00. The current price Pliant Therapeutics (PLRX) is trading at is $12.52, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.